POST-(NEO)ADJUVANT THERAPY OUTCOMES WITH LENVATINIB PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER: RESULTS FROM STUDY 309/KEYNOTE-775 AND ENGOT-EN9/LEAP-001 | Publicación